Germany's Degussa 9 months results

20 August 1995

- Germany's Degussa Group, a dealer in metals and manufacturers of chemicals and pharmaceuticals, posted results for the nine months to June 30, 1995, that showed sales up 3% to 10.5 billion Deutschemarks ($7.3 billion) and income before taxes of 281 million marks, a rise of 51% on the like, year-earlier period. Sales in the pharmaceutical sector were down 1% to 1.63 billion marks, which, according to the group, was due to the effect of lower gold quotations on its dental business. Without the precious metal influences, the group says that sales would have risen by 2%. In addition, the Asta Medica Group recorded sales that were significantly higher than the like, 1994 period.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight